These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

437 related items for PubMed ID: 26682782

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The Effects of Novel Antidiabetic Drugs on Albuminuria in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Luo Y, Lu K, Liu G, Wang J, Laurent I, Zhou X.
    Clin Drug Investig; 2018 Dec; 38(12):1089-1108. PubMed ID: 30255388
    [Abstract] [Full Text] [Related]

  • 4. Diabetes Update: New Pharmacotherapy for Type 2 Diabetes.
    Choby B.
    FP Essent; 2017 May; 456():27-35. PubMed ID: 28530382
    [Abstract] [Full Text] [Related]

  • 5. Complementing insulin therapy to achieve glycemic control.
    Barnett AH.
    Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
    [Abstract] [Full Text] [Related]

  • 6. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
    Yandrapalli S, Jolly G, Horblitt A, Sanaani A, Aronow WS.
    Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Change in glycated haemoglobin levels after initiating second-line therapy in type 2 diabetes: a primary care database study.
    Rathmann W, Bongaerts B, Kostev K.
    Diabetes Obes Metab; 2016 Aug; 18(8):840-3. PubMed ID: 27062643
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis.
    Zhou JB, Tang X, Han M, Yang J, Simó R.
    Metabolism; 2020 Aug; 109():154265. PubMed ID: 32446679
    [Abstract] [Full Text] [Related]

  • 11. Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network meta-analysis.
    Tang H, Li G, Zhao Y, Wang F, Gower EW, Shi L, Wang T.
    Diabetes Obes Metab; 2018 May; 20(5):1262-1279. PubMed ID: 29369494
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: Systematic review and meta-analysis.
    Foroutan N, Muratov S, Levine M.
    Clin Invest Med; 2016 Apr 02; 39(2):E48-62. PubMed ID: 27040861
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
    Mamza J, Mehta R, Donnelly R, Idris I.
    Ann Med; 2016 Apr 02; 48(4):224-34. PubMed ID: 26982210
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials.
    Monami M, Cremasco F, Lamanna C, Marchionni N, Mannucci E.
    Diabetes Metab Res Rev; 2011 May 02; 27(4):362-72. PubMed ID: 21309062
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.